Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.70 |
| ▸ | JAK3 | P52333 | 8/20 | 0.68 |
| ▸ | BTK | Q06187 | 9/20 | 0.63 |
| ▸ | JAK2 | O60674 | 3/20 | 0.63 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | FES | P07332 | 1/20 | 0.58 |
| ▸ | FER | P16591 | 1/20 | 0.58 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.58 |
| ▸ | TEC | P42680 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17002236 | 0.92 | EGFR (0.82) | EGFRJAK3BTKJAK2GAK | |
| SCHEMBL17002254 | 0.90 | EGFR (0.85) | EGFRJAK3BTKJAK2GAK | |
| SCHEMBL18371454 | 0.90 | JAK3 (0.71) | EGFRJAK3BTKJAK2 | |
| SCHEMBL16706317 | 0.90 | JAK3 (0.71) | EGFRJAK3BTKJAK2TEC | |
| SCHEMBL17002253 | 0.88 | EGFR (0.72) | EGFRJAK3BTKGAKFES | |
| SCHEMBL16706316 | 0.87 | JAK3 (0.68) | EGFRJAK3BTKJAK2 | |
| SCHEMBL15130636 | 0.84 | JAK3 (0.64) | EGFRJAK3BTKJAK2 | |
| SCHEMBL17002258 | 0.84 | EGFR (0.74) | EGFRJAK3BTKGAKFES | |
| SCHEMBL28059334 | 0.84 | BTK (0.85) | EGFRJAK3BTKJAK2ERBB3 | |
| SCHEMBL17002251 | 0.83 | EGFR (0.72) | EGFRJAK3BTKGAKFES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167264-B2 | Substituted pyrimidines useful as EGFR-T790M kinase inhibitors | JIANGSU MEDOLUTION LTD (CN) | 2019-01-01 | — | — | US | disclosed |
| US-20170008856-A1 | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | JIANGSU MEDOLUTION LTD (CN) | 2017-01-12 | — | — | US | disclosed |
| WO-2015117547-A1 | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | JIANGSU MEDOLUTION LIMITED (CN) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167264-B2 | Substituted pyrimidines useful as EGFR-T790M kinase inhibitors | EGFR, ERBB2, ERBB3 | EGFR 1/4885JAK3 65/4885BTK 233/4885 |
| US-20170008856-A1 | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885JAK3 65/4885BTK 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.